Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.

Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, Goodman SG, Goldenberg RM, Al-Omran M, Gilbert RE, Bhatt DL, Leiter LA, Jüni P, Zinman B, Connelly KA.

Circulation. 2019 Nov 19;140(21):1693-1702. doi: 10.1161/CIRCULATIONAHA.119.042375. Epub 2019 Aug 22.

PMID:
31434508
2.

Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice.

Fitchett DH.

Eur Endocrinol. 2018 Sep;14(2):40-49. doi: 10.17925/EE.2018.14.2.40. Epub 2018 Sep 10. Review.

3.

Management of Acute Coronary Syndromes.

Diabetes Canada Clinical Practice Guidelines Expert Committee, Tardif JC, L'Allier PL, Fitchett DH.

Can J Diabetes. 2018 Apr;42 Suppl 1:S190-S195. doi: 10.1016/j.jcjd.2017.10.029. No abstract available.

PMID:
29650095
4.

Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.

Fitchett DH, Udell JA, Inzucchi SE.

Eur J Heart Fail. 2017 Jan;19(1):43-53. doi: 10.1002/ejhf.633. Epub 2016 Sep 21. Review.

5.

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ.

Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28. Review.

PMID:
27470878
6.

Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations.

Fitchett DH, Goodman SG, Leiter LA, Lin P, Welsh R, Stone J, Grégoire J, Mcfarlane P, Langer A.

Can J Cardiol. 2016 Jul;32(7 Suppl):S15-34. doi: 10.1016/j.cjca.2016.03.002. Epub 2016 Mar 10.

PMID:
27342696
7.

Cardiology patient page. Statin intolerance.

Fitchett DH, Hegele RA, Verma S.

Circulation. 2015 Mar 31;131(13):e389-91. doi: 10.1161/CIRCULATIONAHA.114.013189. No abstract available.

PMID:
25825402
8.

Cardiology Patient Page: coronary artery revascularization in patients with diabetes mellitus.

Fitchett DH, Gupta M, Farkouh ME, Verma S.

Circulation. 2014 Sep 16;130(12):e104-6. doi: 10.1161/CIRCULATIONAHA.113.007968. No abstract available.

PMID:
25223776
9.

Risk stratification and selection for statin therapy: going beyond Framingham.

Fitchett DH, Mancini GB, Gregoire J, Anderson T, McPherson R.

Can J Cardiol. 2014 Jun;30(6):667-70. doi: 10.1016/j.cjca.2014.03.006. Epub 2014 Mar 12.

PMID:
24882539
10.

Management of acute coronary syndromes.

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Tardif JC, L'Allier PL, Fitchett DH.

Can J Diabetes. 2013 Apr;37 Suppl 1:S119-23. doi: 10.1016/j.jcjd.2013.01.034. Epub 2013 Mar 26. No abstract available.

PMID:
24070931
11.

Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials.

Verma S, Farkouh ME, Yanagawa B, Fitchett DH, Ahsan MR, Ruel M, Sud S, Gupta M, Singh S, Gupta N, Cheema AN, Leiter LA, Fedak PW, Teoh H, Latter DA, Fuster V, Friedrich JO.

Lancet Diabetes Endocrinol. 2013 Dec;1(4):317-28. doi: 10.1016/S2213-8587(13)70089-5. Epub 2013 Sep 13.

PMID:
24622417
12.

A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care.

Teoh H, Després JP, Dufour R, Fitchett DH, Goldin L, Goodman SG, Harris SB, Langer A, Lau DC, Lonn EM, Mancini GB, McFarlane PA, Poirier P, Rabasa-Lhoret R, Tan MK, Leiter LA.

Diabetes Obes Metab. 2013 Dec;15(12):1093-100. doi: 10.1111/dom.12134. Epub 2013 Jun 11.

PMID:
23683111
13.

Identification and management of patients at elevated cardiometabolic risk in canadian primary care: how well are we doing?

Teoh H, Després JP, Dufour R, Fitchett DH, Goldin L, Goodman SG, Harris SB, Langer A, Lau DC, Lonn EM, John Mancini GB, McFarlane PA, Poirier P, Rabasa-Lhoret R, Tan MK, Leiter LA.

Can J Cardiol. 2013 Aug;29(8):960-8. doi: 10.1016/j.cjca.2012.12.001. Epub 2013 Mar 7.

PMID:
23465284
14.

Potential role of rivaroxaban in patients with acute coronary syndrome.

Fitchett DH.

Drug Des Devel Ther. 2012;6:349-57. doi: 10.2147/DDDT.S30342. Epub 2012 Nov 22. Review.

15.

Managing cardiometabolic risk in primary care: summary of the 2011 consensus statement.

Chatterjee A, Harris SB, Leiter LA, Fitchett DH, Teoh H, Bhattacharyya OK; Cardiometabolic Risk Working Group (Canadian).

Can Fam Physician. 2012 Apr;58(4):389-93, e196-201. Review. English, French. No abstract available.

16.

Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study.

Braga MF, Casanova A, Teoh H, Gerstein HC, Fitchett DH, Honos G, McFarlane PA, Ur E, Yale JF, Langer A, Goodman SG, Leiter LA; Diabetes Registry to Improve Vascular Events [DRIVE] Investigators.

Int J Clin Pract. 2012 May;66(5):457-64. doi: 10.1111/j.1742-1241.2012.02894.x. Epub 2012 Mar 27.

PMID:
22452524
17.

Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 2: ST-segment elevation myocardial infarction.

Fitchett DH, Theroux P, Brophy JM, Cantor WJ, Cox JL, Gupta M, Kertland H, Mehta SR, Welsh RC, Goodman SG.

Can J Cardiol. 2011 Nov-Dec;27 Suppl A:S402-12. doi: 10.1016/j.cjca.2011.08.107. Review.

PMID:
22118043
18.

Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 1: non-ST-segment elevation ACS.

Fitchett DH, Theroux P, Brophy JM, Cantor WJ, Cox JL, Gupta M, Kertland H, Mehta SR, Welsh RC, Goodman SG.

Can J Cardiol. 2011 Nov-Dec;27 Suppl A:S387-401. doi: 10.1016/j.cjca.2011.08.110. Review.

PMID:
22118042
19.

Acute coronary syndromes: a Canadian perspective.

Fitchett DH.

Can J Cardiol. 2011 Nov-Dec;27 Suppl A:S385-6. doi: 10.1016/j.cjca.2011.10.003. No abstract available.

PMID:
22118041
20.

Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.

Quinlan DJ, Eikelboom JW, Goodman SG, Welsh RC, Fitchett DH, Théroux P, Mehta SR.

Eur Heart J. 2011 Sep;32(18):2256-65. doi: 10.1093/eurheartj/ehr143. Epub 2011 May 30. Review.

PMID:
21624900
21.

Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary).

Cardiometabolic Risk Working Group: Executive Committee, Leiter LA, Fitchett DH, Gilbert RE, Gupta M, Mancini GB, McFarlane PA, Ross R, Teoh H, Verma S, Anand S, Camelon K, Chow CM, Cox JL, Després JP, Genest J, Harris SB, Lau DC, Lewanczuk R, Liu PP, Lonn EM, McPherson R, Poirier P, Qaadri S, Rabasa-Lhoret R, Rabkin SW, Sharma AM, Steele AW, Stone JA, Tardif JC, Tobe S, Ur E.

Can J Cardiol. 2011 Mar-Apr;27(2):124-31. doi: 10.1016/j.cjca.2011.01.016. Review.

PMID:
21459258
22.

Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group.

Cardiometabolic Risk Working Group: Executive Committee, Leiter LA, Fitchett DH, Gilbert RE, Gupta M, Mancini GB, McFarlane PA, Ross R, Teoh H, Verma S, Anand S, Camelon K, Chow CM, Cox JL, Després JP, Genest J, Harris SB, Lau DC, Lewanczuk R, Liu PP, Lonn EM, McPherson R, Poirier P, Qaadri S, Rabasa-Lhoret R, Rabkin SW, Sharma AM, Steele AW, Stone JA, Tardif JC, Tobe S, Ur E.

Can J Cardiol. 2011 Mar-Apr;27(2):e1-e33. doi: 10.1016/j.cjca.2010.12.054. Review.

PMID:
21459257
23.

Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI).

Yan AT, Yan RT, Cantor WJ, Borgundvaag B, Cohen EA, Fitchett DH, Dzavik V, Ducas J, Tan M, Casanova A, Goodman SG; TRANSFER-AMI Investigators.

Eur Heart J. 2011 Aug;32(16):1994-2002. doi: 10.1093/eurheartj/ehr008. Epub 2011 Feb 8.

PMID:
21307037
24.

Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatients.

Bhan V, Yan RT, Leiter LA, Fitchett DH, Langer A, Lonn E, Tan M, Silagy S, Goodman SG, Yan AT; Guidelines Oriented Approach in Lipid Lowering (GOALL) Registry and Vascular Protection (VP) Registry Investigators.

Am J Cardiol. 2010 Nov 1;106(9):1270-6. doi: 10.1016/j.amjcard.2010.06.055.

PMID:
21029823
25.

Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge.

Bagnall AJ, Yan AT, Yan RT, Lee CH, Tan M, Baer C, Polasek P, Fitchett DH, Langer A, Goodman SG; Canadian Acute Coronary Syndromes Registry II Investigators.

Circ Cardiovasc Qual Outcomes. 2010 Sep;3(5):530-7. doi: 10.1161/CIRCOUTCOMES.109.919415. Epub 2010 Aug 17.

PMID:
20716715
26.

Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada.

Braga M, Casanova A, Teoh H, Dawson KC, Gerstein HC, Fitchett DH, Harris SB, Honos G, McFarlane PA, Steele A, Ur E, Yale JF, Langer A, Goodman SG, Leiter LA; Diabetes Registry to Improve Vascular Events (DRIVE) Investigators.

Can J Cardiol. 2010 Jun-Jul;26(6):297-302.

27.

Acute coronary thrombosis in a patient with diabetes and severe hyperglycemia.

Roberts JD, Oudit GY, Fitchett DH.

Can J Cardiol. 2009 Jun;25(6):e217-9.

28.

Influence of age on use of cardiac catheterization and associated outcomes in patients with non-ST-elevation acute coronary syndromes.

Bagnall AJ, Goodman SG, Fox KA, Yan RT, Gore JM, Cheema AN, Huynh T, Chauret D, Fitchett DH, Langer A, Yan AT; Canadian Acute Coronary Syndrome Registry I and II Investigators; Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators.

Am J Cardiol. 2009 Jun 1;103(11):1530-6. doi: 10.1016/j.amjcard.2009.01.369. Epub 2009 Apr 8.

PMID:
19463511
29.

Understanding physicians' risk stratification of acute coronary syndromes: insights from the Canadian ACS 2 Registry.

Yan AT, Yan RT, Huynh T, Casanova A, Raimondo FE, Fitchett DH, Langer A, Goodman SG; Canadian Acute Coronary Syndrome Registry 2 Investigators.

Arch Intern Med. 2009 Feb 23;169(4):372-8. doi: 10.1001/archinternmed.2008.563.

PMID:
19237721
30.

Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals?

Saposnik G, Goodman SG, Leiter LA, Yan RT, Fitchett DH, Bayer NH, Casanova A, Langer A, Yan AT; Vascular Protection; Guidelines-Oriented Approach to Lipid-Lowering Registries Investigators; Stroke Outcome Research Canada Working Group.

Stroke. 2009 Apr;40(4):1417-24. doi: 10.1161/STROKEAHA.108.533018. Epub 2009 Feb 12.

PMID:
19213947
31.

Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial.

Yan AT, Yan RT, Huynh T, DeYoung P, Weeks A, Fitchett DH, Langer A, Goodman SG; INTERACT Investigators.

Am Heart J. 2008 Oct;156(4):769-75. doi: 10.1016/j.ahj.2008.05.022. Epub 2008 Jul 21.

PMID:
18926160
33.

Impact of delayed presentation on management and outcome of non-ST-elevation acute coronary syndromes.

Elbarouni B, Goodman SG, Yan RT, Casanova A, Al-Hesayen A, Pearce S, Fitchett DH, Langer A, Yan AT; Canadian ACS Registries Investigators.

Am Heart J. 2008 Aug;156(2):262-8. doi: 10.1016/j.ahj.2008.03.025. Epub 2008 Jun 17.

PMID:
18657655
34.

Resting heart rate: a modifiable prognostic indicator of cardiovascular risk and outcomes?

Arnold JM, Fitchett DH, Howlett JG, Lonn EM, Tardif JC.

Can J Cardiol. 2008 May;24 Suppl A:3A-8A. Review.

35.

Quantitative troponin elevation does not provide incremental prognostic value beyond comprehensive risk stratification in patients with non-ST-segment elevation acute coronary syndromes.

Lim KD, Yan AT, Casanova A, Yan RT, Mendelsohn A, Jolly S, Fitchett DH, Langer A, Goodman SG; Canadian ACS Registry II Investigators.

Am Heart J. 2008 Apr;155(4):718-24. doi: 10.1016/j.ahj.2007.11.012. Epub 2008 Feb 21.

PMID:
18371482
36.

Missed opportunities for the secondary prevention of cardiovascular disease in Canada.

Hackam DG, Leiter LA, Yan AT, Yan RT, Mendelsohn A, Tan M, Zavodni L, Chen R, Tsang JL, Kundi A, Lin PJ, Fitchett DH, Langer A, Goodman SG; Vascular Protection Registry and Guideline Oriented Appraoch to Lipid Lowering Registry Investigators.

Can J Cardiol. 2007 Dec;23(14):1124-30.

37.

Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome.

Yan AT, Yan RT, Tan M, Huynh T, Soghrati K, Brunner LJ, DeYoung P, Fitchett DH, Langer A, Goodman SG; Canadian ACS Registries Investigators.

Am Heart J. 2007 Dec;154(6):1108-15. Epub 2007 Sep 14.

PMID:
18035083
38.

Local hospital vs. core-laboratory interpretation of the admission electrocardiogram in acute coronary syndromes: increased mortality in patients with unrecognized ST-elevation myocardial infarction.

Vijayaraghavan R, Yan AT, Tan M, Fitchett DH, Georgescu AA, Hassan Q, Langer A, Goodman SG; Canadian Acute Coronary Syndromes Registry Investigators.

Eur Heart J. 2008 Jan;29(1):31-7. Epub 2007 Nov 6.

PMID:
17989080
39.

Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes.

Yan AT, Yan RT, Tan M, Fung A, Cohen EA, Fitchett DH, Langer A, Goodman SG; Canadian Acute Coronary Syndromes 1 and 2 Registry Investigators.

Arch Intern Med. 2007 May 28;167(10):1009-16.

PMID:
17533203
40.

Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better.

Yan AT, Yan RT, Tan M, Casanova A, Labinaz M, Sridhar K, Fitchett DH, Langer A, Goodman SG.

Eur Heart J. 2007 May;28(9):1072-8. Epub 2007 Apr 16.

PMID:
17437970
41.

Long-term prognostic value and therapeutic implications of continuous ST-segment monitoring in acute coronary syndrome.

Yan AT, Yan RT, Tan M, Senaratne M, Fitchett DH, Langer A, Goodman SG; INTERACT Investigators.

Am Heart J. 2007 Apr;153(4):500-6.

PMID:
17383285
42.

Future strategies for improving outcomes in patients with diabetes and acute coronary syndromes.

Fitchett DH.

Future Cardiol. 2007 Mar;3(2):115-21. doi: 10.2217/14796678.3.2.115. No abstract available.

43.

Bedtime administration of graded-release diltiazem in patients with inadequate BP control: a tolerability and efficacy study.

Fitchett DH, Casanova A, Jaffer S, Tan M, Kornilova O, Goodman SG, Langer A; Outpatient Program with Tiazac XC in the Management of Hypertension (OPTIM) Investigators.

Am J Cardiovasc Drugs. 2006;6(6):393-400.

PMID:
17192129
44.

Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes.

Yan RT, Yan AT, Tan M, McGuire DK, Leiter L, Fitchett DH, Lauzon C, Lai K, Chow CM, Langer A, Goodman SG; Canadian Acute Coronary Syndrome Registry Investigators.

Am Heart J. 2006 Oct;152(4):676-83.

PMID:
16996832
45.

Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.

Fitchett DH, Leiter LA, Goodman SG, Langer A.

Can J Cardiol. 2006 Aug;22(10):835-9. Review.

46.

Contemporary management of dyslipidemia in high-risk patients: targets still not met.

Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H, Tsang JL, Jaffer S, Kates ML, Leiter LA, Fitchett DH, Langer A, Goodman SG; Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators.

Am J Med. 2006 Aug;119(8):676-83.

PMID:
16887414
47.

ST-segment depression in non-ST elevation acute coronary syndromes: quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification.

Yan AT, Yan RT, Tan M, Chow CM, Fitchett DH, Georgescu AA, Hassan Q, Luchansky J, Langer A, Goodman SG; Canadian ACS Registry Investigators.

Am Heart J. 2006 Aug;152(2):270-6.

PMID:
16875907
48.

Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm.

Fitchett DH, Borgundvaag B, Cantor W, Cohen E, Dhingra S, Fremes S, Gupta M, Heffernan M, Kertland H, Husain M, Langer A, Letovsky E, Goodman SG; Renewal of Non STE ACS Algorism Group.

Can J Cardiol. 2006 Jun;22(8):663-77. Review.

50.

Age-related differences in the management and outcome of patients with acute coronary syndromes.

Yan RT, Yan AT, Tan M, Chow CM, Fitchett DH, Ervin FL, Cha JY, Langer A, Goodman SG; Canadian Acute Coronary Syndromes (ACS) Registry Investigators.

Am Heart J. 2006 Feb;151(2):352-9.

PMID:
16442898

Supplemental Content

Loading ...
Support Center